These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 35039637)

  • 1. CD19/BAFF-R dual-targeted CAR T cells for the treatment of mixed antigen-negative variants of acute lymphoblastic leukemia.
    Wang X; Dong Z; Awuah D; Chang WC; Cheng WA; Vyas V; Cha SC; Anderson AJ; Zhang T; Wang Z; Szymura SJ; Kuang BZ; Clark MC; Aldoss I; Forman SJ; Kwak LW; Qin H
    Leukemia; 2022 Apr; 36(4):1015-1024. PubMed ID: 35039637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting FLT3-specific chimeric antigen receptor T cells for acute lymphoblastic leukemia with KMT2A rearrangement.
    Suematsu M; Yagyu S; Yoshida H; Osone S; Nakazawa Y; Sugita K; Imamura T; Iehara T
    Cancer Immunol Immunother; 2023 Apr; 72(4):957-968. PubMed ID: 36214866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies.
    Qin H; Dong Z; Wang X; Cheng WA; Wen F; Xue W; Sun H; Walter M; Wei G; Smith DL; Sun X; Fei F; Xie J; Panagopoulou TI; Chen CW; Song JY; Aldoss I; Kayembe C; Sarno L; Müschen M; Inghirami GG; Forman SJ; Kwak LW
    Sci Transl Med; 2019 Sep; 11(511):. PubMed ID: 31554741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor efficacy of BAFF-R targeting CAR T cells manufactured under clinic-ready conditions.
    Dong Z; Cheng WA; Smith DL; Huang B; Zhang T; Chang WC; Wang X; Forman SJ; Kwak LW; Qin H
    Cancer Immunol Immunother; 2020 Oct; 69(10):2139-2145. PubMed ID: 32451682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loop CD20/CD19 CAR-T cells eradicate B-cell malignancies efficiently.
    Chen Z; Liu Y; Chen N; Xing H; Tian Z; Tang K; Rao Q; Xu Y; Wang Y; Wang M; Wang J
    Sci China Life Sci; 2023 Apr; 66(4):754-770. PubMed ID: 36251156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Translational development of a novel BAFF-R CAR-T therapy targeting B-cell lymphoid malignancies.
    Luo Y; Qie Y; Gadd ME; Manna A; Rivera-Valentin R; To T; Li S; Yassine F; Murthy HS; Dronca R; Kharfan-Dabaja MA; Qin H
    Cancer Immunol Immunother; 2023 Dec; 72(12):4031-4047. PubMed ID: 37814001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence of long-lasting anti-CD19 activity of engrafted CD19 chimeric antigen receptor-modified T cells in a phase I study targeting pediatrics with acute lymphoblastic leukemia.
    Ma F; Ho JY; Du H; Xuan F; Wu X; Wang Q; Wang L; Liu Y; Ba M; Wang Y; Luo J; Li J
    Hematol Oncol; 2019 Dec; 37(5):601-608. PubMed ID: 31465532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR.
    Shalabi H; Qin H; Su A; Yates B; Wolters PL; Steinberg SM; Ligon JA; Silbert S; DéDé K; Benzaoui M; Goldberg S; Achar S; Schneider D; Shahani SA; Little L; Foley T; Molina JC; Panch S; Mackall CL; Lee DW; Chien CD; Pouzolles M; Ahlman M; Yuan CM; Wang HW; Wang Y; Inglefield J; Toledo-Tamula MA; Martin S; Highfill SL; Altan-Bonnet G; Stroncek D; Fry TJ; Taylor N; Shah NN
    Blood; 2022 Aug; 140(5):451-463. PubMed ID: 35605184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD19/CD20 dual-targeted chimeric antigen receptor-engineered natural killer cells exhibit improved cytotoxicity against acute lymphoblastic leukemia.
    Yang N; Zhang C; Zhang Y; Fan Y; Zhang J; Lin X; Guo T; Gu Y; Wu J; Gao J; Zhao X; He Z
    J Transl Med; 2024 Mar; 22(1):274. PubMed ID: 38475814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
    Schultz L
    Front Immunol; 2020; 11():1985. PubMed ID: 32849662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD19/CD22 targeting with cotransduced CAR T cells to prevent antigen-negative relapse after CAR T-cell therapy for B-cell ALL.
    Ghorashian S; Lucchini G; Richardson R; Nguyen K; Terris C; Guvenel A; Oporto-Espuelas M; Yeung J; Pinner D; Chu J; Williams L; Ko KY; Walding C; Watts K; Inglott S; Thomas R; Connor C; Adams S; Gravett E; Gilmour K; Lal A; Kunaseelan S; Popova B; Lopes A; Ngai Y; Hackshaw A; Kokalaki E; Carulla MB; Mullanfiroze K; Lazareva A; Pavasovic V; Rao A; Bartram J; Vora A; Chiesa R; Silva J; Rao K; Bonney D; Wynn R; Pule M; Hough R; Amrolia PJ
    Blood; 2024 Jan; 143(2):118-123. PubMed ID: 37647647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia.
    Hu Y; Zhou Y; Zhang M; Ge W; Li Y; Yang L; Wei G; Han L; Wang H; Yu S; Chen Y; Wang Y; He X; Zhang X; Gao M; Yang J; Li X; Ren J; Huang H
    Clin Cancer Res; 2021 May; 27(10):2764-2772. PubMed ID: 33627493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of polyfunctionality for enhanced BAFF-R CAR T-cell therapy for hematologic malignancies.
    Dong Z; Budde LE; Oh E; Szymura S; Anderson A; Del Real M; Cha SC; Forman SJ; Kwak LW; Wang X
    Blood Adv; 2024 Aug; 8(15):4066-4076. PubMed ID: 38885481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent anti-leukemia activities of humanized CD19-targeted Chimeric antigen receptor T (CAR-T) cells in patients with relapsed/refractory acute lymphoblastic leukemia.
    Cao J; Wang G; Cheng H; Wei C; Qi K; Sang W; Zhenyu L; Shi M; Li H; Qiao J; Pan B; Zhao J; Wu Q; Zeng L; Niu M; Jing G; Zheng J; Xu K
    Am J Hematol; 2018 Jul; 93(7):851-858. PubMed ID: 29633386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia.
    Gu R; Liu F; Zou D; Xu Y; Lu Y; Liu B; Liu W; Chen X; Liu K; Guo Y; Gong X; Lv R; Chen X; Zhou C; Zhong M; Wang H; Wei H; Mi Y; Qiu L; Lv L; Wang M; Wang Y; Zhu X; Wang J
    J Hematol Oncol; 2020 Sep; 13(1):122. PubMed ID: 32894185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel CD19 chimeric antigen receptor T cells manufactured next-day for acute lymphoblastic leukemia.
    Zhang C; He J; Liu L; Wang J; Wang S; Liu L; Ge J; Gao L; Gao L; Kong P; Liu Y; Liu J; Han Y; Zhang Y; Sun Z; Ye X; Yin W; Sersch M; Shen L; Cao WW; Zhang X
    Blood Cancer J; 2022 Jun; 12(6):96. PubMed ID: 35750687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells.
    Bai Z; Lundh S; Kim D; Woodhouse S; Barrett DM; Myers RM; Grupp SA; Maus MV; June CH; Camara PG; Melenhorst JJ; Fan R
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34006631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy.
    An L; Lin Y; Deng B; Yin Z; Zhao D; Ling Z; Wu T; Zhao Y; Chang AH; Tong C; Liu S
    BMC Cancer; 2022 Apr; 22(1):393. PubMed ID: 35410148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [In vitro studies on the transfer of CAR into leukemia cells due to their residue in the autologous CAR-T cell preparation system for acute B-cell acute lymphoblastic leukemia].
    Liu MJ; Mu J; Yuan T; Cui R; Meng JX; Jiang YY; Li YM; Deng Q
    Zhonghua Xue Ye Xue Za Zhi; 2021 Feb; 42(2):140-145. PubMed ID: 33858045
    [No Abstract]   [Full Text] [Related]  

  • 20. Dual CAR-T Cells Targeting CD19 and CD37 Are Effective in Target Antigen Loss B-cell Tumor Models.
    Imai K; Takeuchi Y; Terakura S; Okuno S; Adachi Y; Osaki M; Umemura K; Hanajiri R; Shimada K; Murata M; Kiyoi H
    Mol Cancer Ther; 2024 Mar; 23(3):381-393. PubMed ID: 37828726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.